Qianjiang Yongan Pharmaceutical Management

Management criteria checks 2/4

Qianjiang Yongan Pharmaceutical's CEO is Rengui Hong, appointed in Jun 2021, has a tenure of 3.42 years. directly owns 0.062% of the company’s shares, worth CN¥1.49M. The average tenure of the management team and the board of directors is 8.8 years and 3.4 years respectively.

Key information

Rengui Hong

Chief executive officer

CN¥1.9m

Total compensation

CEO salary percentage	n/a
CEO tenure	3.4yrs
CEO ownership	0.06%
Management average tenure	8.8yrs
Board average tenure	3.4yrs

Recent management updates

Recent updates

Qianjiang Yongan Pharmaceutical (SZSE:002365) Is Paying Out A Dividend Of CN¥0.10

Jul 01

Investors Aren't Buying Qianjiang Yongan Pharmaceutical Co., Ltd.'s (SZSE:002365) Revenues

Feb 27

CEO

Rengui Hong (41 yo)

3.4yrs

Tenure

CN¥1,909,100

Compensation

Mr. Rengui Hong is Managing Director and Director of Qianjiang Yongan Pharmaceutical Co. Ltd. from June 28, 2021.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Rengui Hong	MD & Director	3.4yrs	CN¥1.91m	0.062% CN¥ 1.5m
Baineng Luo	Head of the Audit Department	8.2yrs	CN¥522.50k	0.062% CN¥ 1.5m
Shi Hao Dong	Deputy General Manager	18.7yrs	CN¥1.09m	0.37% CN¥ 9.0m
Xiquan Fang	Deputy General Manager	11.3yrs	CN¥1.74m	0.097% CN¥ 2.3m
Zhihua Wang	Deputy General Manager	9.4yrs	CN¥918.30k	0.097% CN¥ 2.3m
Shaobo Li	Senior Management	5.8yrs	CN¥627.70k	0.017% CN¥ 409.9k

8.8yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 002365's management team is seasoned and experienced (8.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Rengui Hong	MD & Director	3.4yrs	CN¥1.91m	0.062% CN¥ 1.5m
Yong Chen	Chairman	18.7yrs	CN¥2.95m	21.79% CN¥ 525.5m
Yuxi Wu	Chairman of the Supervisory Board	3.4yrs	CN¥166.70k	0.19% CN¥ 4.6m
Chunxiang Zhao	Independent Director	3.4yrs	CN¥80.00k	no data
Bing Zhang	Independent Director	3.4yrs	CN¥80.00k	no data
Xu Wu	Supervisor	9.4yrs	no data	no data
Zidi Chen	Non-Independent Director	less than a year	CN¥367.60k	no data
Wen Chen	Independent Director	less than a year	no data	no data

3.4yrs

Average Tenure

46yo

Average Age

Experienced Board: 002365's board of directors are considered experienced (3.4 years average tenure).

Qianjiang Yongan Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Jun 21, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.032 (vs CN¥0.034 loss in 3Q 2023)

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: EPS: CN¥0.081 (vs CN¥0.14 in 2Q 2023)

Qianjiang Yongan Pharmaceutical (SZSE:002365) Is Paying Out A Dividend Of CN¥0.10

Insufficient new directors

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Jun 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.097 (vs CN¥0.051 in 1Q 2023)

Full year 2023 earnings released: CN¥0.042 loss per share (vs CN¥0.48 profit in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investors Aren't Buying Qianjiang Yongan Pharmaceutical Co., Ltd.'s (SZSE:002365) Revenues

Investor sentiment deteriorates as stock falls 27%

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: CN¥0.034 loss per share (vs CN¥0.15 profit in 3Q 2022)

New minor risk - Profit margin trend

Full year 2022 earnings released: EPS: CN¥0.48 (vs CN¥0.38 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.13 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.07 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.32 in 2Q 2020)

Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) completed the acquisition of 35% stake in Wuhan Low-dimensional Materials Research Institute Co., Ltd. from Li Ganghui and Wuhan Xinlian Huida Technology Investment Partnership (Limited Partnership).

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.027 (vs CN¥0.017 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.37 (vs CN¥0.31 in FY 2019)

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥8.66

New 90-day low: CN¥9.00

New 90-day low: CN¥10.03

New 90-day low: CN¥10.32

Third quarter earnings released

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020

New 90-day low: CN¥11.10

New 90-day low: CN¥11.63

Earnings released

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age